SC
CYTK icon

Savant Capital’s Cytokinetics CYTK Stock Holding History

Savant Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Sell
3,972
-62
-2% -$4.45K ﹤0.01% 1433
2026
Q1 		$266K Sell
4,034
-70
-2% -$4.45K ﹤0.01% 1244
2025
Q4 		$261K Sell
4,104
-104
-2% -$6.47K ﹤0.01% 1148
2025
Q3 		$231K Buy
+4,208
New +$173K ﹤0.01% 1165

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Savant Capital's CYTK Position: Q2 2026 in Review

Savant Capital reduced its Cytokinetics (CYTK) stake by 1.5% in Q2 2026, selling an estimated $4.45K and leaving 3,972 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

Savant Capital first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Savant Capital held 3,972 shares of Cytokinetics worth $338K as of Q2 2026.
  • Savant Capital sold 62 Cytokinetics shares in Q2 2026, an estimated $4.45K.
  • Cytokinetics made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1433 holding.
  • Savant Capital first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.